597 related articles for article (PubMed ID: 32250177)
1. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
Yager JL; Anderson PL
Expert Opin Drug Metab Toxicol; 2020 Jun; 16(6):463-474. PubMed ID: 32250177
[TBL] [Abstract][Full Text] [Related]
2. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz R; Reirden D; Glenny C; Malhotra M; Anderson PL; Hosek S
AIDS Res Hum Retroviruses; 2022 Nov; 38(11):840-846. PubMed ID: 35943868
[TBL] [Abstract][Full Text] [Related]
4. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.
Cespedes MS; Das M; Yager J; Prins M; Krznaric I; de Jong J; Xiao D; Shao Y; Wong P; Kintu A; Carter C; Hoornenborg E; Ruane P; Phoenix J; Younis I; Halperin J
Transgend Health; 2024 Feb; 9(1):46-52. PubMed ID: 38312459
[TBL] [Abstract][Full Text] [Related]
5. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.
Yager J; Brooks KM; Brothers J; Mulligan K; Landovitz RJ; Reirden D; Malhotra M; Glenny C; Harding P; Powell T; Anderson PL; Hosek S
AIDS Res Hum Retroviruses; 2022 Dec; 38(12):939-943. PubMed ID: 35815468
[TBL] [Abstract][Full Text] [Related]
6. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
[TBL] [Abstract][Full Text] [Related]
7. Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.
Hiransuthikul A; Janamnuaysook R; Himmad K; Kerr SJ; Thammajaruk N; Pankam T; Phanjaroen K; Mills S; Vannakit R; Phanuphak P; Phanuphak N;
J Int AIDS Soc; 2019 Jul; 22(7):e25338. PubMed ID: 31298497
[TBL] [Abstract][Full Text] [Related]
8. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
[TBL] [Abstract][Full Text] [Related]
9. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
Marins LMS; Torres TS; Leite IDC; Moreira RI; Luz PM; Hoagland B; Kallas EG; Madruga JV; Liu AY; Anderson PL; Grinsztejn B; Veloso VG
PLoS One; 2019; 14(8):e0221281. PubMed ID: 31430318
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
Anderson PL; Reirden D; Castillo-Mancilla J
J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 3(Suppl 3):S230-4. PubMed ID: 27429188
[TBL] [Abstract][Full Text] [Related]
11. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women.
Tanaudommongkon A; Chaturvedula A; Hendrix CW; Fuchs EJ; Shieh E; Bakshi RP; Marzinke MA
Br J Clin Pharmacol; 2022 Aug; 88(8):3674-3682. PubMed ID: 35285974
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
Murewanhema G; Malisheni M; Takah NF
Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
[TBL] [Abstract][Full Text] [Related]
14. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.
Solomon MM; Schechter M; Liu AY; McMahan VM; Guanira JV; Hance RJ; Chariyalertsak S; Mayer KH; Grant RM;
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):281-6. PubMed ID: 26413853
[TBL] [Abstract][Full Text] [Related]
15. Method of Calculating Renal Function Estimates Could Inappropriately Exclude Transgender Patients Receiving Gender-Affirming Hormone Therapy from Pre-Exposure Prophylaxis Eligibility.
Patel N; Blumenthal J; Dubé MP; Hood A; Bolan R; Morris S
LGBT Health; 2022 Apr; 9(3):199-206. PubMed ID: 35196473
[No Abstract] [Full Text] [Related]
16. No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis.
Patel N; Morris S; Burke L; Chow K; Pacheco D; Anderson P; Stancyzk F; Blumenthal J
Br J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38646796
[TBL] [Abstract][Full Text] [Related]
17. Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
Cattani VB; Jalil EM; Eksterman L; Torres T; Cardoso SW; Castro CRV; Monteiro L; Wilson E; Bushman L; Anderson P; Veloso VG; Grinsztejn B; Estrela R;
J Antimicrob Chemother; 2022 Sep; 77(10):2729-2736. PubMed ID: 35815666
[TBL] [Abstract][Full Text] [Related]
18. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
20. Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.
Stalter RM; Pintye J; Mugwanya KK
Expert Opin Drug Saf; 2021 Nov; 20(11):1367-1373. PubMed ID: 33998936
[No Abstract] [Full Text] [Related]
[Next] [New Search]
